Meeting
2018 ASCO Annual Meeting
METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).
Authors
Marcia Hall
Mount Vernon Cancer Centre, Middlesex, United Kingdom
Marcia Hall , Hakim-Moulay Debhi , Shibani Nicum , Rosemary Lord , Susana N. Banerjee , Andrew R. Clamp , Rachel Lilleywhite , Rosalind Margaret Glasspool , Amanda Feeney , Allan Hackshaw , Jonathan A. Ledermann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01610869
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5551)
DOI
10.1200/JCO.2018.36.15_suppl.5551
Abstract #
5551
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Agnieszka Michael
Poster
2016 ASCO Annual Meeting
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
First Author: Yasutoshi Kuboki
Poster
2013 ASCO Annual Meeting
A phase II study of oral metronomic combination therapy in relapsed epithelial ovarian cancer.
First Author: Sudeep Gupta
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter